secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950142-23-000510
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals CCO Robert Besthof resigns; hires Windhaul Partners for commercial strategy
--------------------------------------------------------------------------------

- Robert Besthof, Head of Operations and CCO, resigned effective Feb 16, 2023; will stay for transition.
- Company in discussions with Besthof for part-time advisor role.
- Hired Windhaul Partners and President Frank Sanders (ex-Sage Therapeutics) to advise on expanded commercial plan.
- FDA recommended expanded 'Chronic/Intermittent' indication for lead compound NRX-101, prompting expanded commercial strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000095014223000510/0000950142-23-000510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000095014223000510/eh230333134_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-23-000510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer